Miltenyi Biotec
Bergisch Gladbach, Germany
Compare CAR-T CDMOs in Europe
Compare CAR-T CDMOs in Germany
Compare Cell Therapy CDMOs in Europe
Compare Cell Therapy CDMOs in Germany
8 confirmed programs
· 8 sponsors
· Last scored 2026-10-29
73.0
Signal Score
○ FDA Inspections
✓ Clinical Trials (8)
○ SEC Filings
✓ Press (16)
✓ EMA GMP (2)
○ MHRA GMP
✓ HC GMP (1)
Quick Facts: Miltenyi Biotec
- Signal Score
- 73.0/100 (as of 2026-10-29)
- Quality Compliance
- 100.0/100
- Headquarters
- Bergisch Gladbach, Germany
- Modalities
- CAR-T, Cell Therapy
- Active Programs
- 8 confirmed from ClinicalTrials.gov across 8 sponsors
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Miltenyi Biotec
Pure-play CDMO.
Signal Score & Pillar Breakdown
Quality Compliance
100.0
FDA InspectionsNo US records on file
EMA GMP Certificates2 on record
Most Recent HC OutcomeCompliant · 2018-03-21
HC Attribution1 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Operations
57.5
8 active programs across 8 sponsors
Modalities: CAR-T, Cell Therapy
2 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
8 active programs across 8 sponsors · Modalities: CAR-T, Cell Therapy · 2 programs in advanced phases (Phase 2/3)
Programs
8
Sponsors8
ModalitiesCAR-T, Cell Therapy
8 active programs across 8 sponsors
Modalities: CAR-T, Cell Therapy
2 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
Partnership Signals (from press monitoring)
Company announcements, not verified evidence.
CHA Biotech, Miltenyi Biotec collaborate on scalable CAR-NK manufacturing - koreabiomed.com
2026-04-28
Cha Biotech partners with Miltenyi Biotec to advance CAR-NK therapy in Korea - CHOSUNBIZ - Chosunbiz
2026-04-28
Cha Biotech Partners With Miltenyi Biotec to Develop Allogeneic CAR-NK Cancer Therapy - aju press
2026-04-28
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
58.0
1 manufacturing site: Bergisch Gladbach, DE
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
Sites: Bergisch Gladbach, DE
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
Press Signals16 articles (not scored)
1 manufacturing site: Bergisch Gladbach, DE
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
Miltenyi Biotec EMA GMP Compliance 2 certificates
2025-06
2024-09
Compliant
Non-Compliant
| Certificate | Site | Country | Inspection Date | Status |
|---|---|---|---|---|
| DE_NW_04_GMP_2025_0046 | Miltenyi Biotec B.V. & Co. KG | Germany | 2025-06-18 | COMPLIANT |
| DE_MV_01_GMP_2025_0017 | Miltenyi Biotec B.V. & Co. KG | Germany | 2024-09-19 | COMPLIANT |
Source: EMA EudraGMDP · Retrieved Nov 21, 2026
Clinical Activity 8 studies
NCT07192900
Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
PHASE1
Recruiting
NCT05705570
Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory...
PHASE1
Recruiting
NCT05094206
CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies
PHASE1
Terminated
NCT05281809
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell...
PHASE2
Recruiting
NCT04464434
Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous...
PHASE4
Completed
NCT01033617
IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem Cells in Patients...
NA
Completed
NCT00595127
Hematopoietic Stem Cell Transplantation for Treatment of Patients With...
NA
Completed
NCT01881334
Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients...
NA
Available
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source:
public careers pages
· Checked Nov 20, 2026
Company Signals 16 articles
Company announcements, not verified evidence. They do not change any score.
GMP Cytokines Market Key Players | Miltenyi Biotec, ABCAM, Akron Biotech, REPROCELL Inc etc. - openPR.com
GMP Cytokines Market Key Players | Miltenyi Biotec, ABCAM, Akron Biotech, REPROCELL Inc etc. openPR.com
CHA Biotech, Miltenyi Biotec collaborate on scalable CAR-NK manufacturing - koreabiomed.com
CHA Biotech, Miltenyi Biotec collaborate on scalable CAR-NK manufacturing koreabiomed.com
Cha Biotech partners with Miltenyi Biotec to advance CAR-NK therapy in Korea - CHOSUNBIZ - Chosunbiz
Cha Biotech partners with Miltenyi Biotec to advance CAR-NK therapy in Korea - CHOSUNBIZ Chosunbiz
Cha Biotech Partners With Miltenyi Biotec to Develop Allogeneic CAR-NK Cancer Therapy - aju press
Cha Biotech Partners With Miltenyi Biotec to Develop Allogeneic CAR-NK Cancer Therapy aju press
Cha Biotech partners with Miltenyi Biotec to advance CAR-NK therapy in Korea - CHOSUNBIZ - Chosunbiz
Cha Biotech partners with Miltenyi Biotec to advance CAR-NK therapy in Korea - CHOSUNBIZ Chosunbiz
Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform - Manufacturing Chemist
Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform Manufacturing Chemist
Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform - Manufacturing Chemist
Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform Manufacturing Chemist
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy - MSN
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy MSN
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy - MSN
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy MSN
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy - MSN
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy MSN
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy - MSN
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy MSN
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy - MSN
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy MSN
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy - MSN
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy MSN
Miltenyi Biotec sprints for the CAR-T finish line amid rising Big Pharma consolidation - ET Pharma
Miltenyi Biotec sprints for the CAR-T finish line amid rising Big Pharma consolidation ET Pharma
Miltenyi Biotec weighs local CGT manufacturing, eyes export potential - Business Standard
Miltenyi Biotec weighs local CGT manufacturing, eyes export potential Business Standard
Miltenyi Biotec sees big India opportunity as it advances Made‑for‑India CAR‑T therapies - Moneycontrol.com
Miltenyi Biotec sees big India opportunity as it advances Made‑for‑India CAR‑T therapies Moneycontrol.com
Frequently Asked Questions About Miltenyi Biotec
Does Miltenyi Biotec hold EMA or MHRA GMP certificates?
CDMO Signal tracks 2 EMA GMP certificates for Miltenyi Biotec.
How many clinical programs is Miltenyi Biotec linked to?
Miltenyi Biotec is associated with 8 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Miltenyi Biotec's CDMO Signal Score?
Miltenyi Biotec has a Signal Score of 73/100, based on quality, operations, financial stability, and capacity data.
Evaluating Miltenyi Biotec for a manufacturing program?
Use the free AI matchmaker to compare Miltenyi Biotec against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Cellex Cell Professionals
Cologne, Germany
Signal Score: 59.0
Cell Therapy, CAR-T
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 87.0
CAR-T, Cell Therapy
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
City of Hope (T Cell Manufacturing)
Duarte, CA
Signal Score: 84.0
CAR-T, Cell Therapy
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score: 83.1
CAR-T, Cell Therapy
Compare Miltenyi Biotec with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.